|
Target Audience
Psychiatrists
Learning Objective
After discussing data related to impairments in academic performance, social
relationships, and driving behaviors, you will be able to evaluate the benefits
of ADHD treatment for adolescents. You will also be better able to tailor an
effective treatment strategy to meet the needs of your adolescent patients and
improve overall functional outcomes.
Accreditation/Designation of Credit Statements
Veritas Institute for Medical Education, Inc. is accredited by the Accreditation
Council for Continuing Medical Education to provide continuing medical education
for physicians.
Veritas Institute for Medical
Education, Inc. designates this educational activity for a maximum of 0.5
AMA PRA Category 1 CreditsTM. Physicians should only claim
credit commensurate with the extent of their participation in the activity.
Financial Disclosure Statements
In accordance with the ACCME’s Standards for Commercial Support, all CME
providers are required to disclose to the activity audience the relevant
financial relationships of the planners, teachers, and authors involved in the
development of CME content. An individual has a relevant financial relationship
if he or she has a financial relationship in any amount occurring in the last 12
months with a commercial interest whose products or services are discussed in
the CME activity content over which the individual has control. Disclosures are
as follows:
Jeffrey Newcorn, MD―Cephalon
Inc, Cortex Pharmaceuticals Inc, Eli Lilly and Company, Novartis Pharmaceuticals
Corporation, Ortho-McNeil, Pfizer Inc, Shire (grant/research support, speakers
bureau, and/or consultant).
Timothy E. Wilens, MD―Abbott
Laboratories, Cephalon Inc, Eli Lilly and Company, Janssen Pharmaceutica
Products LP, National Institute of Mental Health, National Institute on Drug
Abuse, NeuroSearch, Novartis Pharmaceuticals Corporation, Ortho-McNeil, Pfizer
Inc, Shire (grant/research support, speakers bureau, and/or consultant).
The staff of Veritas Institute for
Medical Education, Inc. has nothing to disclose.
Unlabeled Use Disclosure
Statement
Participants are advised that this CME activity will contain references to
unlabeled/unapproved/investigational uses of guanfacine,
clonidine, methylphenidate, amphetamine compounds, and atomoxetine.
Method of Participation
Listen to the prerecorded telesymposium and complete the CME Activity Posttest
and Evaluation and Request for Credit forms. You will receive your CME
certificate immediately. This activity is provided free of charge to
participating physicians.
|
Managing ADHD Impairments in Adolescents
Transitioning to Adulthood
Jeffrey Newcorn, MD
Release Date: May 2007
Expiration Date: April 30, 2008
Please enter a valid e-mail address in the space below to access the
CME Activity Posttest and Evaluation and Request for Credit forms.
 |